Peer-reviewed veterinary case report
Surgery and carboplatin chemo for advanced cat mammary cancer survival
By De Campos, Cecilia Bonolo et al.·Published in In vivo (Athens, Greece)·2014·School of Agricultural and Veterinary Sciences of the Sao Paulo State University (FCAV/UNESP) - Jaboticabal Campus, Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of surgery and carboplatin in feline malignant mammary gland neoplasms with advanced clinical staging.
- Species:
- cat
Plain-English summary
A group of 16 cats with advanced mammary cancer underwent surgery to remove tumors, with some also receiving chemotherapy with a drug called carboplatin. The cats that had both surgery and chemotherapy lived longer than those who only had surgery, but the difference wasn't significant enough to draw strong conclusions. While surgery is still the best treatment option for this type of cancer, the effectiveness of adding carboplatin remains uncertain. More research is needed to explore additional treatments for these cats.
People also search for: cat mammary cancer treatment · feline mammary tumor surgery · carboplatin for cats · cat cancer survival rates
Abstract
BACKGROUND/AIM: Feline mammary carcinomas (FMCs) are characterized by poor prognosis and little progress has been made in extending patient survival. The aim of the study was to compare overall survival periods of FMCs submitted to different treatment protocols, including surgery and adjuvant chemotherapy. MATERIALS AND METHODS: Analysis of conventional surgical excision alone or in association with adjuvant chemotherapy with carboplatin in sixteen cats diagnosed with stage III and grade II or III FMCs was performed. RESULTS: Patients treated with surgery and chemotherapy presented a longer overall survival (OS) than those treated only with surgery, however, no statistical difference was observed when comparing both treatments (p=0.883). CONCLUSION: Therapeutic benefit of carboplatin remains invalidated for FMCs and further investigation regarding adjuvant therapies are warranted. Surgery remains as the gold treatment in FMCs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25189900/